RxDoctor Payments Data

Nicholas Parkinson

Family · Cincinnati, OHNPI 1093195638

Payments from drug & device makers

$3,177in general payments, 2019–2025

Across 175 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$573
  • Lilly USA, LLC$323
  • Novo Nordisk$288
  • AstraZeneca$285
  • Pfizer$202
  • GSK$179
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,177 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$41,951
Medicare patients
255
Services billed
678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$50,270
FarxigaDapagliflozin Propanediol19$26,861
TrulicityDulaglutide14$22,273
EliquisApixaban25$20,946
JanuviaSitagliptin Phosphate13$9,614
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,779
Gabapentin47$918
Atorvastatin Calcium152$878
Albuterol Sulfate HfaAlbuterol Sulfate31$787
Omeprazole44$602
Pantoprazole Sodium39$582
Levothyroxine Sodium59$574
SynthroidLevothyroxine Sodium13$527
Metoprolol Succinate56$462
Ezetimibe11$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$153$50,27035 claims
AstraZenecaFarxiga$285$26,86119 claims
Lilly USA, LLCTrulicity$323$22,27314 claims
PfizerEliquis$202$20,94625 claims
MerckJanuvia$92$9,61413 claims
AbbVieSynthroid$573$52713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →